Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) EBITDA Margin: 2014-2020

Historic EBITDA Margin for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to 1,196.68%.

  • Larimar Therapeutics' EBITDA Margin fell 141892.00% to 1,196.68% in Q1 2020 from the same period last year, while for Mar 2020 it was 2,288.58%, marking a year-over-year decrease of 72555.00%. This contributed to the annual value of 2,567.27% for FY2019, which is 66471.00% down from last year.
  • As of Q1 2020, Larimar Therapeutics' EBITDA Margin stood at 1,196.68%, which was down 40.31% from 2,004.70% recorded in Q4 2019.
  • In the past 5 years, Larimar Therapeutics' EBITDA Margin ranged from a high of 163,937.50% in Q4 2017 and a low of 1,196.68% during Q1 2020.
  • In the last 3 years, Larimar Therapeutics' EBITDA Margin had a median value of 2,920.84% in 2018 and averaged 2,703.62%.
  • Per our database at Business Quant, Larimar Therapeutics' EBITDA Margin spiked by 15,316,121bps in 2017 and then slumped by 16,101,666bps in 2018.
  • Quarterly analysis of 5 years shows Larimar Therapeutics' EBITDA Margin stood at 10,776.29% in 2016, then spiked by 15,316,121bps to 163,937.50% in 2017, then crashed by 16,101,666bps to 2,920.84% in 2018, then plummeted by 91,615bps to 2,004.70% in 2019, then tumbled by 141,892bps to 1,196.68% in 2020.
  • Its EBITDA Margin stands at 1,196.68% for Q1 2020, versus 2,004.70% for Q4 2019 and 3,028.87% for Q3 2019.